News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Scribe Therapeutics recommended long ahead of platform readouts, offering asymmetric upside if CRISPR delivery and efficacy are validated.
  • Sandisk pitch says stock is oversold, targets $2,000 with entry $1,320 and stop $1,150 over 180 trading days.
  • MasTec positioned as a cheap way to play data-center and grid modernization, entry $190 target $235 stop $172.
  • Analysts point to AI infrastructure demand and tight NAND supply as support for Sandisk's rebound case.
  • All three trade ideas include defined entries, stops, targets, and time horizons for disciplined swing or platform trades.

Latest Articles

Micron: Buy the Buyback, Sit Through Slower Content Growth

Micron: Buy the Buyback, Sit Through Slower Content Growth

Micron just reported blockbuster Q4 results and fat guidance, but we think the smartest near-term trade is to own the stock to capture continued pricing tailwinds and an accelerated capital-return program while monitoring content growth metrics. Entry $1109.73, target $1350.00, stop $980.00; swing trade (45 trading days) with the option to convert …

Yen Strengthens on Hot Tokyo Inflation as Dollar Pauses Ahead of US Payrolls

Yen Strengthens on Hot Tokyo Inflation as Dollar Pauses Ahead of US Payrolls

The dollar eased modestly on Friday after expectations of weaker-than-anticipated US payrolls reduced near-term rate-hike anxiety. A surprise rise in Tokyo consumer prices lifted the Japanese yen and supported bets on further Bank of Japan tightening, while a sharp jump in euro zone headline inflation maintained pressure on the European Central Ban…

Global Bond Markets React to Weaker U.S. Jobs Data; French Yields Hit 2002 Highs as Bunds Slide to One-Week Lows

Global Bond Markets React to Weaker U.S. Jobs Data; French Yields Hit 2002 Highs as Bunds Slide to One-Week Lows

U.S. Treasury yields shifted after a much softer-than-expected September jobs report, with intermediate maturities rallying as markets dialed back expectations for near-term Federal Reserve tightening. French 10-year yields hovered near levels last seen in 2002 amid investor concern over Paris's budget plans, while German 10-year Bunds fell to one-…

StoneX Group Inc. Acquires Integra Trading S.A.S., Establishing a Colombian Coffee Origination and Processing Platform

StoneX Group Inc. Acquires Integra Trading S.A.S., Establishing a Colombian Coffee Origination and Processing Platform

StoneX Group Inc. has signed a definitive agreement to acquire Integra Trading S.A.S., a Colombian coffee trading, exporting, and processing company. The acquisition, conducted through StoneX's Swiss trading entity, will enhance StoneX's physical commodities business by increasing its direct origination and processing footprint in Colombia, improvi…

Liberty Defense and Wadsworth Solutions Announce Sale of HEXWAVE™ Systems to Cleveland Hopkins International Airport

Liberty Defense and Wadsworth Solutions Announce Sale of HEXWAVE™ Systems to Cleveland Hopkins International Airport

Liberty Defense Holdings Ltd. announced that Cleveland Hopkins International Airport will deploy two of its HEXWAVE systems to enhance the Aviation Worker Screening program. The AI-powered HEXWAVE system detects metallic and non-metallic threats using advanced millimeter wave technology and 3D imaging, providing comprehensive security screening. Wa…

Cycurion Regains Compliance with Nasdaq Bid Price Requirement

Cycurion Regains Compliance with Nasdaq Bid Price Requirement

Cycurion, Inc., a cybersecurity and AI solutions provider, announced it has regained compliance with Nasdaq's minimum bid price requirement following a 1-for-8 reverse stock split. The company’s stock has remained above the $1.00 threshold for over 10 consecutive trading days, preventing delisting and allowing continued trading under the ticker CYC…

Ruanyun Announces Preliminary Unaudited First-Half Fiscal 2027 Revenue in the Range of US$9.3 Million to US$9.5 Million

Ruanyun Announces Preliminary Unaudited First-Half Fiscal 2027 Revenue in the Range of US$9.3 Million to US$9.5 Million

Ruanyun Edai Technology Inc. expects its preliminary unaudited revenue for the first half of fiscal 2027 to be between $9.3 million and $9.5 million, significantly increasing from $0.37 million in the same period last year. This growth is primarily fueled by its Smart Campus Services business launched in September 2025, which accounts for over half…

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

Scienture Holdings, Inc. announced that its proprietary oral suspension formulation of losartan, Arbli™, has been added to the formularies of three prominent U.S. pediatric academic medical centers. This milestone enhances Arbli's presence in the pediatric healthcare market. The product addresses a significant $219 million U.S. losartan market by o…

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics announced nonclinical data demonstrating effective glycemic control, scalable manufacturing, and successful engraftment of their iPSC-derived islet replacement therapy, CNTY-813. The company is on track to submit an IND in Q4 2026 and anticipates initial clinical data in the second half of 2027, highlighting advancements toward…

Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation

Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation

Autonomix Medical announced issuance of Canadian Patent No. 3,183,802, which expands protection for their catheter-based transvascular intervention technologies that enable precise access, adaptive treatment delivery, and real-time procedural validation in nerve-targeted therapies. This patent complements existing U.S. and European patents, reinfor…

Thunder Bridge Capital Partners V, Ltd. Announces Separate Trading of its Class A Ordinary Shares and Warrants, Commencing October 5, 2026

Thunder Bridge Capital Partners V, Ltd. Announces Separate Trading of its Class A Ordinary Shares and Warrants, Commencing October 5, 2026

Thunder Bridge Capital Partners V, Ltd., a blank check company listed on Nasdaq, announced that holders of its units sold in the IPO can elect to separate and trade Class A ordinary shares and warrants individually starting October 5, 2026. The shares and warrants will trade under symbols TBCV and TBCVW respectively, while unseparated units will co…

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

Surrozen, Inc. announced FDA clearance of its Investigational New Drug (IND) application for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist, to treat diabetic macular edema (DME). This milestone enables initiation of the Phase 1b/2a DUET study expected in Q4 2026 and triggers the second closing of a private placement anticipated to raise …

Satellogic Announces Successful Launch of First Merlin Satellite

Satellogic Announces Successful Launch of First Merlin Satellite

Satellogic Inc. announced the successful launch of its first Merlin satellite along with additional NewSat satellites into low-Earth orbit, marking a significant milestone in deploying its Persistent Global Intelligence infrastructure. The Merlin satellite constellation will provide global detection and theater-scale monitoring with onboard AI proc…

Celcuity Appoints David Gryska To Its Board Of Directors

Celcuity Appoints David Gryska To Its Board Of Directors

Celcuity Inc., a biotechnology firm focused on targeted therapies for solid tumors, has appointed David Gryska to its Board of Directors. Mr. Gryska brings over 35 years of strategic and financial experience in life sciences, including CFO roles and board memberships at multiple biotech companies. This appointment comes as Celcuity transitions into…

NETSOL Technologies appoints Michael Ramsey as Vice President of Sales for Asset Finance in the Americas

NETSOL Technologies appoints Michael Ramsey as Vice President of Sales for Asset Finance in the Americas

NETSOL Technologies, Inc. announced the appointment of Michael Ramsey as Vice President of Sales for its Transcend Finance platform in the Americas. Ramsey brings over 30 years of experience in asset finance enterprise sales and will lead growth initiatives in the U.S., the largest asset finance market globally. This strategic hire aligns with NETS…

Hyperion DeFi Commences Share Buybacks, Retires All Legacy Debt, and Commits to Further Capital Optimization

Hyperion DeFi Commences Share Buybacks, Retires All Legacy Debt, and Commits to Further Capital Optimization

Hyperion DeFi, Inc. announced repurchasing over 240,000 shares at a $3.21 average price, fully retiring $8.6 million of legacy debt, and positioning itself for further capital structure optimization. The company aims to leverage its debt-free status and $14.5 million in cash and equivalents to scale its Hyperliquid blockchain ecosystem and DeFi ope…

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome

Teva Pharmaceuticals disclosed new data demonstrating that ecopipam, their investigational treatment for pediatric Tourette syndrome, shows significant tic severity reduction in about 70% of patients within 8 weeks and sustained efficacy with no new safety concerns during long-term follow-up. The drug's efficacy is unaffected by common co-occurring…